HC Wainwright & Co. Maintains Buy on Compass Therapeutics, Maintains $10 Price Target

Benzinga · 03/21 15:15
HC Wainwright & Co. analyst Joseph Pantginis maintains Compass Therapeutics (NASDAQ:CMPX) with a Buy and maintains $10 price target.